Healthcare

Julie Grant

General Partner / West Coast

Since 2013

Julie leads investments and company formation efforts in biopharma that tangibly improve patient care. Since joining Canaan in 2013, Julie has incubated, financed and supported investments in multiple new biopharmaceutical companies including Day One Biopharmaceuticals (DAWN), Reactive Biosciences, Nocion, Synthekine, Protagonist (PTGX), Cellular Research (Acquired by Becton Dickinson), Dermira (DERM), Labrys Biologics, CytomX (CTMX), and Unchained Labs.

Prior to joining Canaan, Julie worked at Genentech bringing new oncology products to market in roles spanning business development, cross functional management and commercial. Julie serves on The National Cancer Advisory Board, appointed by President Biden in 2023. She holds an M.B.A. from Stanford’s Graduate School of Business, a M.Phil. from Cambridge University in BioScience Enterprise and a B.S. in Molecular Biophysics and Biochemistry from Yale University.

Julie in 5

Origins: Grew up next to The Second City in Chicago

Interests: Maintaining a strict diet of daily dark chocolate consumption

Travel: Weekend skiing & hiking retreats in the Western mountain ranges

Accomplishments: College sailing national champion

Bucket List: Skiing in Japan

Investments

Previous

Latest

Endpoints News: Nocion raises $62M for different approach to chronic cough than Merck, GSK

Julie Grant to be Appointed to National Cancer Advisory Board

Endpoints News: Day One to file NDA for pediatric brain cancer drug by summer

FierceBiotech: A new day for pediatric cancer patients: Day One's share price doubles on initial data for brain tumor drug

The Long Run Podcast: Julie Grant and Sam Blackman on cancer drugs for kids

Silicon Valley Business Journal: Investors pile on Stanford spinout promising new ways to attack cancer, autoimmune diseases

Endpoints News: It’s a new $DAWN for Day One as startup pivots to an IPO for more funding to back its work in pediatric cancer

Reconvening for a virtual Women Who Venture gathering

Fierce Biotech: Childhood cancer-focused Day One banks $130M for pan-RAF inhibitor

SF Business Times: Targeting more childhood cancers, Day One raises $130M

Endpoints News: With 'rapid' progress of pediatric brain cancer treatment, Day One sees broad excitement in new crossover round

Timmerman Report: No longer an afterthought -- Day One raises $130M for childhood cancer therapies

MedCity News: Consumer awareness, needs generating shifts in precision medicine landscape

BioCentury: Larger stakes, more newcos as Canaan moves to bump up biopharma investments with new $800M fund

Endpoints News: Canaan raises another $800M as it launches its next fund with an emphasis on biotech

BioCentury: Gilead BD head Bender takes top job at pediatric cancer start-up Day One

Fierce Biotech: Childhood cancer-focused Day One snags Gilead alum Bender for CEO

Fierce Biotech: Synthekine debuts with $82M, Stanford tech to create a new generation of cytokine therapies

Endpoints News: A longtime CytomX exec re-emerges at Synthekine, an $82M Stanford spinout

Fierce Biotech: Nocion grabs new CMO as it kicks off COVID-19 cough study

MedCityNews: Julie Grant on how the pandemic has changed investing

FierceBiotech: COVID-19 close-up: Nocion CEO Batycky on controlling cough to control spread

WSJ Pro VC: Cancer drugmaker Day One Biopharmaceuticals launches with $60 million

STAT News: Startup Spotlight - Aiming to speed precision cancer therapies to children

Julie Grant: Cancer drug development comes of age - The inspiration behind Day One Biopharmaceuticals

FierceBiotech: Day One debuts with $60M to change cancer care—starting with children

MedCity News: How are healthcare VCs in every sector handling Covid-19?

BioCentury: We’ve moved on from nude women parties. That’s only a small part of the progress.

Annual Women Who Venture Gathering 2020

FierceBiotech: Canaan Partners promotes Julie Grant to general partner

Growth from within: Brendan Dickinson and Julie Grant promoted to General Partners

FierceBiotech: Nocion Therapeutics named to Fierce 15

FierceBiotech: Nocion launches with $27M and 'charged drugs' to selectively target pain

Business Insider: Nocion raises $27M to make a new kind of painkiller as the race to replace opioids heats up

STAT News: How one company, Nocion, thinks unraveling cough can provide a new way to treat pain

Julie Grant: Announcing Nocion Therapeutics, a novel approach to neurogenic inflammation

Business Insider: Julie Grant named 40-and-under Silicon Valley biotech investing star

Nina Kjellson: In case of emergency -- expert tips for weathering a crisis

Endpoints Under 40 Feature: Julie Grant’s views on the future of biopharma

Spotlight on Wende Hutton’s 25 years in venture capital

STAT News: Julie Grant on how biotech’s latest bubble might go pop

CNBC: After a miserable 2017, VCs offer predictions on digital health IPOs for 2018

CNBC: 11 women who prove that health tech investing isn’t a boys’ club

Fierce Biotech: Canaan unveils $800 million fund for fresh wave of biotech bets

BioTech Nation Podcast: Women in biotech venture capital

SF Business Times: Life sciences veterans reflect on the past, present and future of Bay Area biotech

Silicon Valley Business Journal: Women of Influence 2017

Protagonist Therapeutics

Julie in 5

Origins: Grew up next to The Second City in Chicago

Interests: Maintaining a strict diet of daily dark chocolate consumption

Travel: Weekend skiing & hiking retreats in the Western mountain ranges

Accomplishments: College sailing national champion

Bucket List: Skiing in Japan